© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Jan 24, 2015, the consensus forecast amongst 3 polled investment analysts covering GW Pharmaceuticals plc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jul 28, 2014. The previous consensus forecast advised investors to purchase equity in GW Pharmaceuticals plc.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 2 analysts offering 12 month price targets for GW Pharmaceuticals plc have a median target of 365.00, with a high estimate of 380.00 and a low estimate of 350.00. The median estimate represents a -9.82 % decrease from the last price of 404.75. View Full Financials
Dividend information is not available for GW Pharmaceuticals PLC. View Full Financials
On Dec 02, 2014, GW Pharmaceuticals plc reported 4th quarter 2014 breakeven earnings per share.
The next earnings announcement is expected on Feb 04, 2015. View Full Interim Financials
|Average growth rate||-28.00 %|
GW Pharmaceuticals plc reported annual 2014 losses of -0.070 per share on Dec 02, 2014. View Full Annual Financials
|Average growth rate||-61.50 %|
GW Pharmaceuticals plc had 3rd quarter 2014 revenues of 7.61m. This missed the 467.84m consensus estimate of the 3 analysts following the company. This was 1.12% above the prior year's 3rd quarter results. View Full Interim Financials
|Average growth rate||+0.83 %|
GW Pharmaceuticals plc had revenues for the full year 2014 of 30.05m. This was 10.08% above the prior year's results. View Full Annual Financials
|Average growth rate||+0.21 %|